Splenomegaly: Difference between revisions
Iqra Qamar (talk | contribs) No edit summary |
(→Causes) |
||
(19 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | |||
{{ | '''For the patient information page for this topic, click [[Splenomegaly (patient information)|here]]''' | ||
{{CMG}}; {{AE}} {{SSH}}, Gichoya Judy Wawira [mailto:judywawira@gmail.com], | |||
{{SK}} Spleen enlargement; enlarged spleen; spleen swelling | {{SK}} Spleen enlargement; enlarged spleen; spleen swelling | ||
==Overview== | |||
==Pathophysiology== | |||
==Causes== | |||
The causes of splenomegaly vary widely and range from increased splenic function (such as [[hemoglobinopathies]]), splenic congestion due to abnormal blood flow (such as venous obstruction), and splenic infiltration (such as storage disorders and [[malignancies]]). | |||
===Causes by Pathogenesis=== | |||
{| class="wikitable" | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mechanism | |||
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Pathogenesis | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Example | |||
|- | |||
! rowspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Increased function | |||
! colspan="2" |Removal of defective RBCs | |||
|<div style="-moz-column-count:2; column-count:2;"> | |||
*[[Spherocytosis]] | |||
*[[Thalassemia]] | |||
*[[Hemoglobinopathy]] | |||
*[[Anemia]] | |||
*[[Sickle cell anemia]]</div> | |||
|- | |||
! rowspan="3" |Immune hyperplasia | |||
!Response to infection (viral, bacterial, fungal, parasitic) | |||
|<div style="-moz-column-count:2; column-count:2;"> | |||
*[[Mononucleosis]] | |||
*[[AIDS]] | |||
*[[Viral hepatitis]] | |||
*[[Endocarditis|Subacute bacterial endocarditis]] | |||
*[[Sepsis|Bacterial septicemia]] | |||
*[[Splenic abscess]] | |||
*[[Typhoid fever]] | |||
*[[Leptospirosis]] | |||
*[[Tuberculosis]] | |||
*[[Histoplasmosis]] | |||
*[[Malaria]] | |||
*[[leishmaniasis]] | |||
*[[Trypanosomiasis]] | |||
*[[Ehrlichiosis]]</div> | |||
|- | |||
!Disordered immunoregulation | |||
|<div style="-moz-column-count:2; column-count:2;"> | |||
*[[Rheumatoid arthritis]] | |||
*[[SLE]] | |||
*[[Serum sickness]] | |||
*[[Autoimmune hemolytic anemia]] | |||
*[[Idiopathic thrombocytopenic purpura|Immune thrombocytopenia]] | |||
*[[Sarcoidosis]]</div> | |||
|- | |||
!Drug reactions | |||
| | |||
*[[Cidofovir]] | |||
*[[Filgrastim]] | |||
|- | |||
! colspan="2" |Extramedullary hematopoiesis | |||
|<div style="-moz-column-count:2; column-count:2;"> | |||
*[[Myelofibrosis]] | |||
*[[Tumors]] | |||
*[[Marrow infiltration by tumors, leukemias|Lukemias]] | |||
*[[marrow damage by radiation, toxins|Marrow damage by radiation]] | |||
*[[marrow damage by radiation, toxins|toxins]]</div> | |||
|- | |||
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Abnormal blood flow | |||
! colspan="2" |Organ Failure | |||
| | |||
*[[Cirrhosis]] | |||
*[[Congestive heart failure]] | |||
|- | |||
! colspan="2" |Vascular | |||
|<div style="-moz-column-count:2; column-count:2;"> | |||
*[[Hepatic vein obstruction]] | |||
*[[Portal vein thrombosis|Portal vein obstruction]] | |||
*[[Budd-Chiari syndrome]] | |||
*Splenic vein obstruction</div> | |||
|- | |||
! colspan="2" |Infections | |||
| | |||
*Hepatic [[schistosomiasis]] | |||
*Hepatic [[echinococcosis]] | |||
|- | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Infiltration | |||
! colspan="2" |Metabolic diseases | |||
|<div style="-moz-column-count:2; column-count:2;"> | |||
*[[Gauchers disease]] | |||
*[[Niemann-Pick disease]] | |||
*[[Hurler syndrome]] | |||
*[[Mucopolysaccharidoses]] | |||
*[[Amyloidosis]] | |||
*[[Tangier disease]]</div> | |||
|- | |||
! colspan="2" |Benign and malignant infiltrations | |||
|<div style="-moz-column-count:2; column-count:2;"> | |||
*[[Leukemias]] ([[acute]], [[chronic]], [[lymphoid]] and [[myeloid]]) | |||
*[[Lymphomas]] ([[Hodgkins]] and [[Non-Hodgkin lymphoma|non-hodgkins]]) | |||
*[[Myeloproliferative]] disorders | |||
*[[Metastatic]] tumors (commonly [[melanoma]]) | |||
*[[Histiocytosis X]] | |||
*[[Hemangioma]] | |||
*[[Lymphangioma]] | |||
*[[Splenic cyst]] | |||
*[[Hamartomas]] | |||
*[[Eosinophilic granuloma]]</div> | |||
|} | |||
==Differentiating Splenomegaly from Other Diseases== | ==Differentiating Splenomegaly from Other Diseases== | ||
{| | {| | ||
Line 47: | Line 152: | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congestive | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congestive | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Cirrhosis]]<ref name="pmid22710653">{{cite journal |vauthors=Wu Z, Zhou J, Pankaj P, Peng B |title=Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity |journal=Surg Endosc |volume=26 |issue=12 |pages=3557–64 |date=December 2012 |pmid=22710653 |doi=10.1007/s00464-012-2366-5 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Cirrhosis]]<ref name="pmid22710653">{{cite journal |vauthors=Wu Z, Zhou J, Pankaj P, Peng B |title=Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity |journal=Surg Endosc |volume=26 |issue=12 |pages=3557–64 |date=December 2012 |pmid=22710653 |doi=10.1007/s00464-012-2366-5 |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Infection]] | * [[Infection]] | ||
* [[Alcohol]] | * [[Alcohol]] | ||
* [[Autoimmunity|Autoimmune]] | * [[Autoimmunity|Autoimmune]] | ||
| align="center" style="background:#F5F5F5;" |Any, more in elderly | | align="center" style="background:#F5F5F5;" |Any age, more common in elderly | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Hepatitis]] | * [[Hepatitis]] | ||
* [[Alcoholism|Alcohol use]] | * [[Alcoholism|Alcohol use]] | ||
Line 78: | Line 183: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Dark [[urine]] | * Dark [[urine]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Pancytopenia]] | * [[Pancytopenia]] | ||
* Regenerating nodules of [[Hepatocyte|hepatocytes]] | * Regenerating nodules of [[Hepatocyte|hepatocytes]] | ||
* [[Fibrosis]] | * [[Fibrosis]] | ||
* Deposition of [[connective tissue]] between these nodules | * Deposition of [[connective tissue]] between these nodules | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Small and nodular [[liver]] on [[ultrasound]] | * Small and nodular [[liver]] on [[ultrasound]] | ||
* [[Fibrosis]] on [[liver]] scan | * [[Fibrosis]] on [[liver]] scan | ||
| align="center" style="background:#F5F5F5;" |[[Liver biopsy]] | | align="center" style="background:#F5F5F5;" |[[Liver biopsy]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Hepatic encephalopathy]] | * [[Hepatic encephalopathy]] | ||
* [[Gynecomastia]] | * [[Gynecomastia]] | ||
Line 96: | Line 201: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Congestive heart failure|Heart failure]]<ref name="pmid26489162">{{cite journal |vauthors=Gedela M, Khan M, Jonsson O |title=Heart Failure |journal=S D Med |volume=68 |issue=9 |pages=403–5, 407–9 |date=September 2015 |pmid=26489162 |doi= |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Congestive heart failure|Heart failure]]<ref name="pmid26489162">{{cite journal |vauthors=Gedela M, Khan M, Jonsson O |title=Heart Failure |journal=S D Med |volume=68 |issue=9 |pages=403–5, 407–9 |date=September 2015 |pmid=26489162 |doi= |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Coronary heart disease|Coronary artery disease]] | * [[Coronary heart disease|Coronary artery disease]] | ||
* [[Hypertension|HTN]] | * [[Hypertension|HTN]] | ||
| align="center" style="background:#F5F5F5;" |Elderly | | align="center" style="background:#F5F5F5;" |Elderly | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Smoking]] | * [[Smoking]] | ||
* Sedentary lifestyle | * Sedentary lifestyle | ||
Line 113: | Line 218: | ||
| align="center" style="background:#F5F5F5;" |± | | align="center" style="background:#F5F5F5;" |± | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Dyspnea]] | * [[Dyspnea]] | ||
* [[Muscle weakness|Weakness]] | * [[Muscle weakness|Weakness]] | ||
Line 127: | Line 232: | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |NA | | align="center" style="background:#F5F5F5;" |NA | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Normal or low [[ejection fraction]] on [[echocardiography]] | * Normal or low [[ejection fraction]] on [[echocardiography]] | ||
* [[Cardiomegaly]] on [[Chest X-ray|chest x-ray]] | * [[Cardiomegaly]] on [[Chest X-ray|chest x-ray]] | ||
| align="center" style="background:#F5F5F5;" |[[Echocardiography]] | | align="center" style="background:#F5F5F5;" |[[Echocardiography]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Pulmonary edema]] | * [[Pulmonary edema]] | ||
* [[Hyponatremia]] | * [[Hyponatremia]] | ||
Line 137: | Line 242: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Thrombosis]] of [[portal]], [[Liver|hepatic]], or [[Splenic vein|splenic veins]]<ref name="pmid22481689">{{cite journal |vauthors=Ferri PM, Ferreira AR, Fagundes ED, Liu SM, Roquete ML, Penna FJ |title=Portal vein thrombosis in children and adolescents: 20 years experience of a pediatric hepatology reference center |journal=Arq Gastroenterol |volume=49 |issue=1 |pages=69–76 |date=2012 |pmid=22481689 |doi= |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Thrombosis]] of [[portal]], [[Liver|hepatic]], or [[Splenic vein|splenic veins]]<ref name="pmid22481689">{{cite journal |vauthors=Ferri PM, Ferreira AR, Fagundes ED, Liu SM, Roquete ML, Penna FJ |title=Portal vein thrombosis in children and adolescents: 20 years experience of a pediatric hepatology reference center |journal=Arq Gastroenterol |volume=49 |issue=1 |pages=69–76 |date=2012 |pmid=22481689 |doi= |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Thrombosis]] | * [[Thrombosis]] | ||
| align="center" style="background:#F5F5F5;" |Any | | align="center" style="background:#F5F5F5;" |Any age | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Inflammation]] | * [[Inflammation]] | ||
* [[Infection]] | * [[Infection]] | ||
Line 154: | Line 259: | ||
| align="center" style="background:#F5F5F5;" |± | | align="center" style="background:#F5F5F5;" |± | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Muscle weakness|Weakness]] | * [[Muscle weakness|Weakness]] | ||
*[[Hematemesis]] | *[[Hematemesis]] | ||
Line 165: | Line 270: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Dark [[urine]] | * Dark [[urine]] | ||
| align="center" style="background:#F5F5F5;" |NA | | align="center" style="background:#F5F5F5;" |NA | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Reduced or absent [[blood flow]] on [[Medical ultrasonography|doppler ultrasonography]] | * Reduced or absent [[blood flow]] on [[Medical ultrasonography|doppler ultrasonography]] | ||
| align="center" style="background:#F5F5F5;" |[[Medical ultrasonography|Doppler ultrasonography]] | | align="center" style="background:#F5F5F5;" |[[Medical ultrasonography|Doppler ultrasonography]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Portal hypertension]] | * [[Portal hypertension]] | ||
* [[Esophageal varices]] | * [[Esophageal varices]] | ||
Line 177: | Line 282: | ||
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy | ! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Lymphoma]]<ref name="pmid25131182">{{cite journal |vauthors=Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Saito T, Tanaka Y |title=Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma |journal=Hematology |volume=20 |issue=4 |pages=203–7 |date=May 2015 |pmid=25131182 |doi=10.1179/1607845414Y.0000000192 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Lymphoma]]<ref name="pmid25131182">{{cite journal |vauthors=Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Saito T, Tanaka Y |title=Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma |journal=Hematology |volume=20 |issue=4 |pages=203–7 |date=May 2015 |pmid=25131182 |doi=10.1179/1607845414Y.0000000192 |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Unknown | * Unknown | ||
* [[Mutation]] | * [[Mutation]] | ||
* [[Infection]] | * [[Infection]] | ||
| align="center" style="background:#F5F5F5;" |Any, most common malignant splenic tumor | | align="center" style="background:#F5F5F5;" |Any age, most common malignant splenic tumor | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Epstein Barr virus]] | * [[Epstein Barr virus]] | ||
* Positive family history | * Positive family history | ||
Line 197: | Line 302: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Lymphadenopathy]] | * [[Lymphadenopathy]] | ||
* [[Itch|Itching]] | * [[Itch|Itching]] | ||
Line 211: | Line 316: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Different [[Histopathology|histopathological]] features based on types and stages | * Different [[Histopathology|histopathological]] features based on types and stages | ||
* [[Reed-Sternberg cell]] | * [[Reed-Sternberg cell]] | ||
* Malignant cells | * Malignant cells | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Peritoneal [[Primary central nervous system lymphoma|lymphomatosis]] on [[Computed tomography|CT scan]] | * Peritoneal [[Primary central nervous system lymphoma|lymphomatosis]] on [[Computed tomography|CT scan]] | ||
| align="center" style="background:#F5F5F5;" |[[Lymph node biopsy]] | | align="center" style="background:#F5F5F5;" |[[Lymph node biopsy]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Immune disorder|Primary immune disorder]] | * [[Immune disorder|Primary immune disorder]] | ||
* Post-[[Organ transplant|transplant]] | * Post-[[Organ transplant|transplant]] | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Leukemia]]<ref name="pmid26614896">{{cite journal |vauthors=Quest GR, Johnston JB |title=Clinical features and diagnosis of hairy cell leukemia |journal=Best Pract Res Clin Haematol |volume=28 |issue=4 |pages=180–92 |date=December 2015 |pmid=26614896 |doi=10.1016/j.beha.2015.10.017 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Leukemia]]<ref name="pmid26614896">{{cite journal |vauthors=Quest GR, Johnston JB |title=Clinical features and diagnosis of hairy cell leukemia |journal=Best Pract Res Clin Haematol |volume=28 |issue=4 |pages=180–92 |date=December 2015 |pmid=26614896 |doi=10.1016/j.beha.2015.10.017 |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Unknown | * Unknown | ||
* [[Mutation]] | * [[Mutation]] | ||
* [[Bone marrow]]<nowiki/>infiltration | * [[Bone marrow]]<nowiki/>infiltration | ||
* Ineffective [[hematopoiesis]] | * Ineffective [[hematopoiesis]] | ||
* [[Immunity (medical)|Immune]] mediated | * [[Immunity (medical)|Immune]] mediated | ||
| align="center" style="background:#F5F5F5;" |Elderly, male>female | | align="center" style="background:#F5F5F5;" |Elderly, male>female | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* History of [[Hematological|hematological disorder]] | * History of [[Hematological|hematological disorder]] | ||
* History of [[chemotherapy]] and[[ionizing radiation]] | * History of [[chemotherapy]] and[[ionizing radiation]] | ||
Line 243: | Line 347: | ||
| align="center" style="background:#F5F5F5;" |± | | align="center" style="background:#F5F5F5;" |± | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Pallor]] | * [[Pallor]] | ||
* [[Chloroma|Leukemia cutis]] | * [[Chloroma|Leukemia cutis]] | ||
Line 249: | Line 353: | ||
* [[Petechia|Petechiae]] | * [[Petechia|Petechiae]] | ||
* [[Ecchymosis]] | * [[Ecchymosis]] | ||
* [[Fatigue]] | * [[Fatigue]] | ||
* Bone [[tenderness]] | * Bone [[tenderness]] | ||
Line 261: | Line 364: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Leukemic blasts | * Leukemic blasts | ||
* Leukoerythroblastic features | * Leukoerythroblastic features | ||
Line 267: | Line 370: | ||
| align="center" style="background:#F5F5F5;" |NA | | align="center" style="background:#F5F5F5;" |NA | ||
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination]] + clinical manifestation | | align="center" style="background:#F5F5F5;" |[[Bone marrow examination]] + clinical manifestation | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Infection|Infections]] of variable severity | * [[Infection|Infections]] of variable severity | ||
* [[Nerve palsy|Cranial nerve palsy]] | * [[Nerve palsy|Cranial nerve palsy]] | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Polycythemia vera|Polycythemia Vera]]<ref name="pmid23281576">{{cite journal |vauthors=Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH |title=Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage |journal=Eur. J. Haematol. |volume=90 |issue=3 |pages=228–36 |date=March 2013 |pmid=23281576 |doi=10.1111/ejh.12064 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Polycythemia vera|Polycythemia Vera]]<ref name="pmid23281576">{{cite journal |vauthors=Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH |title=Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage |journal=Eur. J. Haematol. |volume=90 |issue=3 |pages=228–36 |date=March 2013 |pmid=23281576 |doi=10.1111/ejh.12064 |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Autonomous [[erythrocyte]]<nowiki/>production | * Autonomous [[erythrocyte]]<nowiki/>production | ||
* [[JAK2]]<nowiki/>mutation | * [[JAK2]]<nowiki/>mutation | ||
| align="center" style="background:#F5F5F5;" |Mean age >60 years old | | align="center" style="background:#F5F5F5;" |Mean age >60 years old | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Positive family history | * Positive family history | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
Line 287: | Line 390: | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Erythromelalgia]] | * [[Erythromelalgia]] | ||
* [[Chest pain]] | * [[Chest pain]] | ||
Line 305: | Line 408: | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Elevated normochromic, normocytic [[Red blood cell|RBCs]] | * Elevated normochromic, normocytic [[Red blood cell|RBCs]] | ||
* [[Thrombocytosis]] | * [[Thrombocytosis]] | ||
Line 312: | Line 415: | ||
| align="center" style="background:#F5F5F5;" |NA | | align="center" style="background:#F5F5F5;" |NA | ||
| align="center" style="background:#F5F5F5;" |WHO criteria for [[Polycythemia vera|PV]] | | align="center" style="background:#F5F5F5;" |WHO criteria for [[Polycythemia vera|PV]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Stroke]] | * [[Stroke]] | ||
* [[Venous thrombosis]] | * [[Venous thrombosis]] | ||
Line 346: | Line 449: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Multiple myeloma]]<ref name="pmid3400674">{{cite journal |vauthors=Grieco A, Manna R, Mancini R, Gambassi G |title=Massive hepatomegaly following splenectomy for myeloid metaplasia |journal=Am. J. Med. |volume=84 |issue=4 |pages=797 |date=April 1988 |pmid=3400674 |doi= |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Multiple myeloma]]<ref name="pmid3400674">{{cite journal |vauthors=Grieco A, Manna R, Mancini R, Gambassi G |title=Massive hepatomegaly following splenectomy for myeloid metaplasia |journal=Am. J. Med. |volume=84 |issue=4 |pages=797 |date=April 1988 |pmid=3400674 |doi= |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Unknown | * Unknown | ||
* [[Mutation]] | * [[Mutation]] | ||
* [[Infection]] | * [[Infection]] | ||
| align="center" style="background:#F5F5F5;" |Any, more in adults | | align="center" style="background:#F5F5F5;" |Any age, more common in adults | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Exposure to chemicals | * Exposure to chemicals | ||
* [[Radiation therapy|Radiation]] | * [[Radiation therapy|Radiation]] | ||
Line 364: | Line 467: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Lymphadenopathy]] | * [[Lymphadenopathy]] | ||
* [[Itch|Itching]] | * [[Itch|Itching]] | ||
Line 377: | Line 480: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Hemoglobinuria]] | * [[Hemoglobinuria]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Blast cells | * Blast cells | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination]] | | align="center" style="background:#F5F5F5;" |[[Bone marrow examination]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Tumor lysis syndrome]] | * [[Tumor lysis syndrome]] | ||
* [[Infection]] | * [[Infection]] | ||
Line 390: | Line 493: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Essential thrombocytosis|Essential thrombocythemia]]<ref name="pmid25611051">{{cite journal |vauthors=Tefferi A, Barbui T |title=Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management |journal=Am. J. Hematol. |volume=90 |issue=2 |pages=162–73 |date=February 2015 |pmid=25611051 |doi=10.1002/ajh.23895 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Essential thrombocytosis|Essential thrombocythemia]]<ref name="pmid25611051">{{cite journal |vauthors=Tefferi A, Barbui T |title=Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management |journal=Am. J. Hematol. |volume=90 |issue=2 |pages=162–73 |date=February 2015 |pmid=25611051 |doi=10.1002/ajh.23895 |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Acquired mutation of ''[[Janus kinase|JAK2]], CALR,'' or ''MPL'' | * Acquired mutation of ''[[Janus kinase|JAK2]], CALR,'' or ''MPL'' | ||
| align="center" style="background:#F5F5F5;" |Mean age >60 years old, female > male | | align="center" style="background:#F5F5F5;" |Mean age >60 years old, female > male | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Vascular occlusive events and [[Bleeding|hemorrhages]] | * Vascular occlusive events and [[Bleeding|hemorrhages]] | ||
| align="center" style="background:#F5F5F5;" |± | | align="center" style="background:#F5F5F5;" |± | ||
Line 404: | Line 507: | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Flushing]] | * [[Flushing]] | ||
* [[Erythromelalgia]] | * [[Erythromelalgia]] | ||
Line 418: | Line 521: | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Increased cellularity | * Increased cellularity | ||
* [[Hyperplasia]] and clustering of [[Megakaryocyte|megakaryocytes]] | * [[Hyperplasia]] and clustering of [[Megakaryocyte|megakaryocytes]] | ||
* [[Bone marrow]] [[Reticular fiber|reticulin]] may be increased with no [[collagen]] [[fibrosis]] | * [[Bone marrow]] [[Reticular fiber|reticulin]] may be increased with no [[collagen]] [[fibrosis]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Splenomegaly]] on abdominal CT | * [[Splenomegaly]] on abdominal CT | ||
* [[VTE]] on spiral chest CT | * [[VTE]] on spiral chest CT | ||
* [[Deep vein thrombosis|DVT]] on [[ultrasound]] | * [[Deep vein thrombosis|DVT]] on [[ultrasound]] | ||
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination|Bone marrow biopsy]] | | align="center" style="background:#F5F5F5;" |[[Bone marrow examination|Bone marrow biopsy]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Thrombosis]] | * [[Thrombosis]] | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Myelofibrosis|Primary myelofibrosis]]<ref name="pmid23514013">{{cite journal |vauthors=Cervantes F, Martinez-Trillos A |title=Myelofibrosis: an update on current pharmacotherapy and future directions |journal=Expert Opin Pharmacother |volume=14 |issue=7 |pages=873–84 |date=May 2013 |pmid=23514013 |doi=10.1517/14656566.2013.783019 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Myelofibrosis|Primary myelofibrosis]]<ref name="pmid23514013">{{cite journal |vauthors=Cervantes F, Martinez-Trillos A |title=Myelofibrosis: an update on current pharmacotherapy and future directions |journal=Expert Opin Pharmacother |volume=14 |issue=7 |pages=873–84 |date=May 2013 |pmid=23514013 |doi=10.1517/14656566.2013.783019 |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Bone marrow]] fibrosis | * [[Bone marrow]] fibrosis | ||
* [[Mutation]] in ''[[Janus kinase|JAK2]], CALR'', or ''MPL'' | * [[Mutation]] in ''[[Janus kinase|JAK2]], CALR'', or ''MPL'' | ||
| align="center" style="background:#F5F5F5;" |Mean age >60 years old, male> female | | align="center" style="background:#F5F5F5;" |Mean age >60 years old, male> female | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Other [[Myeloproliferative neoplasm|myeloproliferative]]<nowiki/>disorders | * Other [[Myeloproliferative neoplasm|myeloproliferative]]<nowiki/>disorders | ||
* [[Radioactive contamination|Radiation exposure]] | * [[Radioactive contamination|Radiation exposure]] | ||
Line 448: | Line 551: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Pallor]] | * [[Pallor]] | ||
* [[Bruising]] | * [[Bruising]] | ||
* [[Nodules|Skin nodules]] | * [[Nodules|Skin nodules]] | ||
* [[Nodules|Insert paragraph]] | * [[Nodules|Insert paragraph]] | ||
* [[Fatigue]] | * [[Fatigue]] | ||
* [[Abdominal pain]] | * [[Abdominal pain]] | ||
Line 466: | Line 568: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Urine|Dark urine]] | * [[Urine|Dark urine]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Proliferation and [[atypia]] of [[megakaryocytes]] | * Proliferation and [[atypia]] of [[megakaryocytes]] | ||
* Reticulin or [[Collagen|collagen fibrosis]] | * Reticulin or [[Collagen|collagen fibrosis]] | ||
* Hypercellular [[bone marrow]] | * Hypercellular [[bone marrow]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Diffuse bone [[sclerosis]] on [[CT angiography|CT]] | * Diffuse bone [[sclerosis]] on [[CT angiography|CT]] | ||
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination|Bone marrow biopsy]] | | align="center" style="background:#F5F5F5;" |[[Bone marrow examination|Bone marrow biopsy]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Thrombosis]] | * [[Thrombosis]] | ||
* Variable risk for development of [[acute leukemia]] | * Variable risk for development of [[acute leukemia]] | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Splenic tumor|Primary splenic tumors]]<ref name="pmid21810495">{{cite journal |vauthors=Adachi K, Ui M, Nojima H, Takada Y, Enatsu K |title=Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy |journal=Am. J. Surg. |volume=202 |issue=2 |pages=e17–9 |date=August 2011 |pmid=21810495 |doi=10.1016/j.amjsurg.2010.10.002 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Splenic tumor|Primary splenic tumors]]<ref name="pmid21810495">{{cite journal |vauthors=Adachi K, Ui M, Nojima H, Takada Y, Enatsu K |title=Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy |journal=Am. J. Surg. |volume=202 |issue=2 |pages=e17–9 |date=August 2011 |pmid=21810495 |doi=10.1016/j.amjsurg.2010.10.002 |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Lymphoid neoplasms | * [[Lymphatic system|Lymphoid]] neoplasms | ||
* Vascular neoplasms | * [[Vascular]] neoplasms | ||
| align="center" style="background:#F5F5F5;" |Very rare | | align="center" style="background:#F5F5F5;" |Very rare | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Positive family history | * Positive family history | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 495: | Line 597: | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Lymphadenopathy | * [[Lymphadenopathy]] | ||
* Dyspnea | * [[Dyspnea]] | ||
* Shoulder pain | * Shoulder pain | ||
* Constipation | * [[Constipation]] | ||
* Cachexia | * [[Cachexia]] | ||
* Pleural | * [[Pleural effusion]] | ||
| align="center" style="background:#F5F5F5;" |↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
| align="center" style="background:#F5F5F5;" |↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
Line 509: | Line 611: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Urine|Dark urine]] | * [[Urine|Dark urine]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Different histopathologic features depends on the type of tumor | * Different histopathologic features depends on the type of tumor | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Heterogeneous mass in the [[spleen]] on [[ultrasound]] | * Heterogeneous mass in the [[spleen]] on [[ultrasound]] | ||
* Lymphomatous [[Nodule (medicine)|nodules]] and masses on [[Computed tomography|CT scan]] | * Lymphomatous [[Nodule (medicine)|nodules]] and masses on [[Computed tomography|CT scan]] | ||
| align="center" style="background:#F5F5F5;" |[[Biopsy]] | | align="center" style="background:#F5F5F5;" |[[Biopsy]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Metastasis]] to [[liver]] | * [[Metastasis]] to [[liver]] | ||
* Poor prognosis | * Poor prognosis | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Metastasis|Metastatic solid tumors]]<ref name="pmid24172780">{{cite journal |vauthors=Huprikar NA, Kurtz MT, Mount CA |title=Massive splenomegaly and lymphopenia: a unique case of obstructive shock |journal=BMJ Case Rep |volume=2013 |issue= |pages= |date=October 2013 |pmid=24172780 |pmc=3822246 |doi=10.1136/bcr-2013-201643 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Metastasis|Metastatic solid tumors]]<ref name="pmid24172780">{{cite journal |vauthors=Huprikar NA, Kurtz MT, Mount CA |title=Massive splenomegaly and lymphopenia: a unique case of obstructive shock |journal=BMJ Case Rep |volume=2013 |issue= |pages= |date=October 2013 |pmid=24172780 |pmc=3822246 |doi=10.1136/bcr-2013-201643 |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Bone marrow]]<nowiki/>infiltration | * [[Bone marrow]]<nowiki/>infiltration | ||
* Ineffective [[hematopoiesis]] | * Ineffective [[hematopoiesis]] | ||
* [[Immunity (medical)|Immune]] mediated | * [[Immunity (medical)|Immune]] mediated | ||
| align="center" style="background:#F5F5F5;" |Any, more in adults | | align="center" style="background:#F5F5F5;" |Any age, more in adults | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Exposure to chemicals | * Exposure to chemicals | ||
* [[Radiation therapy|Radiation]] | * [[Radiation therapy|Radiation]] | ||
Line 541: | Line 642: | ||
| align="center" style="background:#F5F5F5;" |± | | align="center" style="background:#F5F5F5;" |± | ||
| align="center" style="background:#F5F5F5;" |± | | align="center" style="background:#F5F5F5;" |± | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Petechia|Petechiae]] | * [[Petechia|Petechiae]] | ||
* [[Muscle weakness|Weakness]] | * [[Muscle weakness|Weakness]] | ||
Line 551: | Line 652: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Urine|Dark urine]] | * [[Urine|Dark urine]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Blast cells | * Blast cells | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |[[Biopsy]] | | align="center" style="background:#F5F5F5;" |[[Biopsy]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Tumor lysis syndrome]] | * [[Tumor lysis syndrome]] | ||
* [[Infection]] | * [[Infection]] | ||
Line 590: | Line 691: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
|- | |- | ||
! rowspan=" | ! rowspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ||
! rowspan="3" align="center" style="background:#DCDCDC;" |[[Virus|Viral]] | ! rowspan="3" align="center" style="background:#DCDCDC;" |[[Virus|Viral]] | ||
! align="center" style="background:#DCDCDC;" |[[Hepatitis]]<ref name="pmid23904062">{{cite journal |vauthors=Kumar KJ, Kumar HC, Manjunath VG, Anitha C, Mamatha S |title=Hepatitis A in children- clinical course, complications and laboratory profile |journal=Indian J Pediatr |volume=81 |issue=1 |pages=15–9 |date=January 2014 |pmid=23904062 |doi=10.1007/s12098-013-1114-8 |url=}}</ref> | ! align="center" style="background:#DCDCDC;" |[[Hepatitis]]<ref name="pmid23904062">{{cite journal |vauthors=Kumar KJ, Kumar HC, Manjunath VG, Anitha C, Mamatha S |title=Hepatitis A in children- clinical course, complications and laboratory profile |journal=Indian J Pediatr |volume=81 |issue=1 |pages=15–9 |date=January 2014 |pmid=23904062 |doi=10.1007/s12098-013-1114-8 |url=}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | |||
* [[Infection]] | |||
* [[Autoimmunity|Autoimmune]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* | * Any age | ||
| align="left" style="background:#F5F5F5;" | | |||
| align=" | |||
* High risk behaviors | * High risk behaviors | ||
* Close contact | * Close contact | ||
Line 609: | Line 711: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Lymphadenopathy]] | * [[Lymphadenopathy]] | ||
* [[Muscle weakness]] | * [[Muscle weakness]] | ||
Line 622: | Line 724: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Urine|Dark urine]] | * [[Urine|Dark urine]] | ||
* [[Hematuria]] | * [[Hematuria]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Pancytopenia]] | * [[Pancytopenia]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |NA | ||
| align="center" style="background:#F5F5F5;" |Clinical manifestation + lab tests | | align="center" style="background:#F5F5F5;" |Clinical manifestation + lab tests | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Depends on etiology | * Depends on etiology | ||
* [[Encephalomyelitis]] | * [[Encephalomyelitis]] | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Mononucleosis|Infectious mononucleosis]]<ref name="pmid21191775">{{cite journal |vauthors=Gao LW, Xie ZD, Liu YY, Wang Y, Shen KL |title=Epidemiologic and clinical characteristics of infectious mononucleosis associated with Epstein-Barr virus infection in children in Beijing, China |journal=World J Pediatr |volume=7 |issue=1 |pages=45–9 |date=February 2011 |pmid=21191775 |doi=10.1007/s12519-011-0244-1 |url=}}</ref> | ! align="center" style="background:#DCDCDC;" |[[Mononucleosis|Infectious mononucleosis]]<ref name="pmid21191775">{{cite journal |vauthors=Gao LW, Xie ZD, Liu YY, Wang Y, Shen KL |title=Epidemiologic and clinical characteristics of infectious mononucleosis associated with Epstein-Barr virus infection in children in Beijing, China |journal=World J Pediatr |volume=7 |issue=1 |pages=45–9 |date=February 2011 |pmid=21191775 |doi=10.1007/s12519-011-0244-1 |url=}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | |||
* [[Epstein Barr virus|EBV]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* | * More common in children and young adults | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | * Close contact | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | + | ||
| align=" | | align="center" style="background:#F5F5F5;" |– | ||
| | | align="left" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | * [[Pharyngitis|Sore throat]] | ||
| align="center" style="background:#F5F5F5;" | | * Enlarged [[Tonsil|tonsils]] | ||
| align="center" style="background:#F5F5F5;" | | * [[Lymphadenopathy]] | ||
| align="center" style="background:#F5F5F5;" | | * [[Headache]] | ||
| align="center" style="background:#F5F5F5;" | | * [[Maculopapular rash]] on the arms or trunk | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl | ||
| align=" | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |Clinical manifestation + [[heterophile antibody test]] | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Splenic rupture]] | |||
* [[Lymphocytosis]] | |||
* [[Seizure|Seizures]] | |||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Cytomegalovirus]]<ref name="pmid25308607">{{cite journal |vauthors=Smiechura M, Strużycka M, Konopka W |title=Congenital and acquired cytomegalovirus infection and hearing evaluation in children |journal=Otolaryngol Pol |volume=68 |issue=6 |pages=303–7 |date=2014 |pmid=25308607 |doi=10.1016/j.otpol.2014.04.003 |url=}}</ref> | ! align="center" style="background:#DCDCDC;" |[[Cytomegalovirus]]<ref name="pmid25308607">{{cite journal |vauthors=Smiechura M, Strużycka M, Konopka W |title=Congenital and acquired cytomegalovirus infection and hearing evaluation in children |journal=Otolaryngol Pol |volume=68 |issue=6 |pages=303–7 |date=2014 |pmid=25308607 |doi=10.1016/j.otpol.2014.04.003 |url=}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | |||
* [[Cytomegalovirus infection|CMV]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align=" | * More common in: | ||
| align="center" style="background:#F5F5F5;" | | ** Immunocompromised patients | ||
| align="center" style="background:#F5F5F5;" | | ** During pregnancy | ||
| align="center" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | * Close contact | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |– | ||
| align=" | | align="center" style="background:#F5F5F5;" |Nl | ||
| | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | * Exudative [[pharyngitis]] | ||
| align="center" style="background:#F5F5F5;" | | * Symmetrical cervical [[Lymphadenopathy|adenopathy]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |[[Enzyme linked immunosorbent assay (ELISA)|ELISA]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! rowspan="3" align="center" style="background:#DCDCDC;" |[[Bacteria|Bacterial]] | ! rowspan="3" align="center" style="background:#DCDCDC;" |[[Bacteria|Bacterial]] | ||
! align="center" style="background:#DCDCDC;" |[[Salmonella]]<ref name="pmid26068006">{{cite journal |vauthors=Rosche KL, Aljasham AT, Kipfer JN, Piatkowski BT, Konjufca V |title=Infection with Salmonella enterica Serovar Typhimurium Leads to Increased Proportions of F4/80+ Red Pulp Macrophages and Decreased Proportions of B and T Lymphocytes in the Spleen |journal=PLoS ONE |volume=10 |issue=6 |pages=e0130092 |date=2015 |pmid=26068006 |pmc=4466801 |doi=10.1371/journal.pone.0130092 |url=}}</ref> | ! align="center" style="background:#DCDCDC;" |[[Salmonella]]<ref name="pmid26068006">{{cite journal |vauthors=Rosche KL, Aljasham AT, Kipfer JN, Piatkowski BT, Konjufca V |title=Infection with Salmonella enterica Serovar Typhimurium Leads to Increased Proportions of F4/80+ Red Pulp Macrophages and Decreased Proportions of B and T Lymphocytes in the Spleen |journal=PLoS ONE |volume=10 |issue=6 |pages=e0130092 |date=2015 |pmid=26068006 |pmc=4466801 |doi=10.1371/journal.pone.0130092 |url=}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | |||
* [[Salmonella]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Any age | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Eating contaminated meat, eggs, or milk | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Diarrhea | |||
* Abdominal cramps | |||
* Vomiting | |||
* Dehydration | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Oliguria]] | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |Stool test | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Typhoid fever | |||
* Reactive arthritis | |||
* Irritable bowel syndrome | |||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Brucella]]<ref name="pmid24983999">{{cite journal |vauthors=Roset MS, Ibañez AE, de Souza Filho JA, Spera JM, Minatel L, Oliveira SC, Giambartolomei GH, Cassataro J, Briones G |title=Brucella cyclic β-1,2-glucan plays a critical role in the induction of splenomegaly in mice |journal=PLoS ONE |volume=9 |issue=7 |pages=e101279 |date=2014 |pmid=24983999 |pmc=4077732 |doi=10.1371/journal.pone.0101279 |url=}}</ref> | ! align="center" style="background:#DCDCDC;" |[[Brucella]]<ref name="pmid24983999">{{cite journal |vauthors=Roset MS, Ibañez AE, de Souza Filho JA, Spera JM, Minatel L, Oliveira SC, Giambartolomei GH, Cassataro J, Briones G |title=Brucella cyclic β-1,2-glucan plays a critical role in the induction of splenomegaly in mice |journal=PLoS ONE |volume=9 |issue=7 |pages=e101279 |date=2014 |pmid=24983999 |pmc=4077732 |doi=10.1371/journal.pone.0101279 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Brucella | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Any age | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Ingesting contaminated food such as unpasteurized milk products | |||
* Direct contact with an infected animal | |||
* Inhalation of aerosols | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Headache | |||
* Vomiting | |||
* Diarrhea | |||
* Constipation | |||
* Arthralgia | |||
* Night sweats | |||
* Anorexia | |||
* Foul-smelling perspiration | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Oliguria]] | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |Blood culture | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Arthritis | |||
* Epididymo-orchitis | |||
* Spondylitis | |||
* Neurobrucellosis | |||
* Liver abscess formation | |||
* Endocarditis | |||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Tuberculosis]]<ref name="pmid27051579">{{cite journal |vauthors=Chandni R, Chandni R, Chandni R |title=Extra pulmonary tuberculosis presenting as fever with massive splenomegaly and pancytopenia |journal=IDCases |volume=4 |issue= |pages=20–2 |date=2016 |pmid=27051579 |pmc=4802818 |doi=10.1016/j.idcr.2016.02.005 |url=}}</ref> | ! align="center" style="background:#DCDCDC;" |[[Tuberculosis]]<ref name="pmid27051579">{{cite journal |vauthors=Chandni R, Chandni R, Chandni R |title=Extra pulmonary tuberculosis presenting as fever with massive splenomegaly and pancytopenia |journal=IDCases |volume=4 |issue= |pages=20–2 |date=2016 |pmid=27051579 |pmc=4802818 |doi=10.1016/j.idcr.2016.02.005 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Mycobacterium tuberculosis | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Any age | |||
* More common in developing countries and among immunocompromised patients | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Close contact | |||
* HIV | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Chronic cough with blood-containing sputum | |||
* Night sweats | |||
* Anorexia | |||
* Chest pain | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Oliguria]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Acid-fast bacillus | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Cavity on chest x ray | |||
| align="center" style="background:#F5F5F5;" |Identifying M. tuberculosis in a clinical sample | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Tuberculous meningitis | |||
* Urogenital tuberculosis | |||
* Pott disease | |||
* Miliary tuberculosis | |||
|- | |- | ||
! rowspan=" | ! rowspan="2" align="center" style="background:#DCDCDC;" |[[Parasitism|Parasitic]] | ||
! align="center" style="background:#DCDCDC;" |[[Malaria]]<ref name="pmid26612502">{{cite journal |vauthors=Sumbele IU, Bopda OS, Kimbi HK, Ning TR, Nkuo-Akenji T |title=Influence of Plasmodium gametocyte carriage on the prevalence of fever, splenomegaly and cardiovascular parameters in children less than 15 years in the Mount Cameroon area: cross sectional study |journal=BMC Infect. Dis. |volume=15 |issue= |pages=547 |date=November 2015 |pmid=26612502 |pmc=4661959 |doi=10.1186/s12879-015-1290-4 |url=}}</ref> | ! align="center" style="background:#DCDCDC;" |[[Malaria]]<ref name="pmid26612502">{{cite journal |vauthors=Sumbele IU, Bopda OS, Kimbi HK, Ning TR, Nkuo-Akenji T |title=Influence of Plasmodium gametocyte carriage on the prevalence of fever, splenomegaly and cardiovascular parameters in children less than 15 years in the Mount Cameroon area: cross sectional study |journal=BMC Infect. Dis. |volume=15 |issue= |pages=547 |date=November 2015 |pmid=26612502 |pmc=4661959 |doi=10.1186/s12879-015-1290-4 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Plasmodium | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Worldwide | |||
* More common in tropical and subtropical regions | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Bitten by Anopheles mosquito | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Flu-like symptoms | |||
* [[Headache]] | |||
* [[Shivering]] | |||
* [[Joint]] pain | |||
* [[Vomiting]] | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Hemoglobinuria]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |NA | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Visceral leishmaniasis|Kala-azar]]<ref name="pmid24850963">{{cite journal |vauthors=Sayyahfar S, Ansari S, Mohebali M, Behnam B |title=Visceral leishmaniasis without fever in an 11-month-old infant: a rare clinical feature of Kala-azar |journal=Korean J. Parasitol. |volume=52 |issue=2 |pages=189–91 |date=April 2014 |pmid=24850963 |pmc=4028457 |doi=10.3347/kjp.2014.52.2.189 |url=}}</ref> | ! align="center" style="background:#DCDCDC;" |[[Visceral leishmaniasis|Kala-azar]]<ref name="pmid24850963">{{cite journal |vauthors=Sayyahfar S, Ansari S, Mohebali M, Behnam B |title=Visceral leishmaniasis without fever in an 11-month-old infant: a rare clinical feature of Kala-azar |journal=Korean J. Parasitol. |volume=52 |issue=2 |pages=189–91 |date=April 2014 |pmid=24850963 |pmc=4028457 |doi=10.3347/kjp.2014.52.2.189 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Leishmaniasis|Leishmania]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Any age | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Bitten by sandflies | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Asymptomatic | |||
* Tender [[spleen]] | |||
* [[Hepatomegaly]] | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Hemoglobinuria]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Visualization of the characteristic amastigote in smears or tissue | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |Culture | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Could be fatal | |||
|- | |- | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease | ||
Line 939: | Line 1,016: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fatigue | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fatigue | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Weight | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Weight | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal pain | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal pain | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ||
Line 961: | Line 1,038: | ||
|- | |- | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Sarcoidosis]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Sarcoidosis]]<ref name="pmid25473783">{{cite journal |vauthors=Modaresi Esfeh J, Culver D, Plesec T, John B |title=Clinical presentation and protocol for management of hepatic sarcoidosis |journal=Expert Rev Gastroenterol Hepatol |volume=9 |issue=3 |pages=349–58 |date=March 2015 |pmid=25473783 |doi=10.1586/17474124.2015.958468 |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Immunity (medical)|Immune]] mediated | * [[Immunity (medical)|Immune]] mediated | ||
* Unknown | * Unknown | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Autoimmune disease]] | |||
* More common in young African American women | |||
| align="left" style="background:#F5F5F5;" | | |||
* Positive family history | * Positive family history | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 975: | Line 1,054: | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |– | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Bilateral [[Hilar lymphadenopathy|hilar adenopathy]] | * Bilateral [[Hilar lymphadenopathy|hilar adenopathy]] | ||
* [[Blurred vision|Blurry vision]] | * [[Blurred vision|Blurry vision]] | ||
Line 992: | Line 1,071: | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |NA | | align="center" style="background:#F5F5F5;" |NA | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Bilateral [[Hilar lymphadenopathy|hilar adenopathy]] on [[Chest X-ray|chest x-ray]] | * Bilateral [[Hilar lymphadenopathy|hilar adenopathy]] on [[Chest X-ray|chest x-ray]] | ||
| align="center" style="background:#F5F5F5;" |Diagnosis of exclusion | | align="center" style="background:#F5F5F5;" |Diagnosis of exclusion | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Interstitial lung disease]] | * [[Interstitial lung disease]] | ||
* Systemic [[Inflammation|inflammatory]]<nowiki/>disease | * Systemic [[Inflammation|inflammatory]]<nowiki/>disease | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Serum sickness]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Serum sickness]]<ref name="pmid26677148">{{cite journal |vauthors=Chiong FJ, Loewenthal M, Boyle M, Attia J |title=Serum sickness-like reaction after influenza vaccination |journal=BMJ Case Rep |volume=2015 |issue= |pages= |date=December 2015 |pmid=26677148 |pmc=4691861 |doi=10.1136/bcr-2015-211917 |url=}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | |||
* Immune complex [[hypersensitivity]] (type III) to certain medications | |||
| | |||
| | |||
| | |||
| align=" | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Any age | |||
| align="left" style="background:#F5F5F5;" | | |||
* Consumption of certain medications | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Rash|Rashes]] | |||
* [[Itch|Itching]] | |||
* Facial [[Edema|swelling]] | |||
* [[Arthralgia]] | |||
* [[Lymphadenopathy]] | |||
* [[Dyspnea]] | |||
| align="center" style="background:#F5F5F5;" |↓ or ↑ | |||
Eosinophilia | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Proteinuria]] | |||
* [[Hematuria]] | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Plasma cell|Plasma cells]] on peripheral blood smear | |||
* Numerous histological changes including [[inflammation]] of arterial wall or [[fibrosis]] | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |Clinical manifestation + recent medication consumption | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Glomerular disease|Glomerulonephritis]] | |||
* [[Shock]] | |||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Systemic lupus erythematosus]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Systemic lupus erythematosus]]<ref name="pmid24461385">{{cite journal |vauthors=Yu C, Gershwin ME, Chang C |title=Diagnostic criteria for systemic lupus erythematosus: a critical review |journal=J. Autoimmun. |volume=48-49 |issue= |pages=10–3 |date=2014 |pmid=24461385 |doi=10.1016/j.jaut.2014.01.004 |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Immune mediated [[Bone marrow suppression|bone marrow failure]] | * Immune mediated [[Bone marrow suppression|bone marrow failure]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* | * More common in young females | ||
| align="left" style="background:#F5F5F5;" | | |||
* Positive family history | |||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 1,041: | Line 1,137: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Rash|Skin rash]] | * [[Rash|Skin rash]] | ||
* [[Oral ulcer|Mouth ulcers]] | * [[Oral ulcer|Mouth ulcers]] | ||
Line 1,053: | Line 1,149: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Hemoglobinuria]] | * [[Hemoglobinuria]] | ||
* [[Proteinuria]] | * [[Proteinuria]] | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Hypocellular [[bone marrow]] | * Hypocellular [[bone marrow]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |Clinical findings + laboratory studies | | align="center" style="background:#F5F5F5;" |Clinical findings + laboratory studies | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Multi organ damage | * Multi organ damage | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Felty's syndrome|Felty syndrome]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Felty's syndrome|Felty syndrome]]<ref name="pmid24472276">{{cite journal |vauthors=Huang T, Liu M, Xu G |title=Felty's syndrome with hyperthyroidism: a case report and literature review |journal=Int J Rheum Dis |volume=17 |issue=1 |pages=122–4 |date=January 2014 |pmid=24472276 |doi=10.1111/1756-185X.12117 |url=}}</ref> | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Immune mediated [[Bone marrow suppression|bone marrow failure]] | * Immune mediated [[Bone marrow suppression|bone marrow failure]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Rare [[autoimmune disease]] | |||
* More common in females 50-70 years old | |||
| align="left" style="background:#F5F5F5;" | | |||
* History of [[rheumatoid arthritis]] | * History of [[rheumatoid arthritis]] | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 1,078: | Line 1,176: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Pallor]] | * [[Pallor]] | ||
* [[Hyperpigmentation|Skin hyperpigmentation]] | * [[Hyperpigmentation|Skin hyperpigmentation]] | ||
* Painful, stiff, and swollen [[Joint|joints]] | * Painful, stiff, and swollen [[Joint|joints]] | ||
* [[Keratoconjunctivitis sicca]] | * [[Keratoconjunctivitis sicca]] | ||
Line 1,092: | Line 1,189: | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Hypocellular [[bone marrow]] | * Hypocellular [[bone marrow]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |Clinical findings + laboratory studies | | align="center" style="background:#F5F5F5;" |Clinical findings + laboratory studies | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* [[Rheumatoid arthritis]] | * [[Rheumatoid arthritis]] | ||
* [[Infection|Infections]] | * [[Infection|Infections]] | ||
|- | |- | ||
! rowspan=" | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infiltrative | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ||
Line 1,107: | Line 1,204: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fatigue | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fatigue | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Weight | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Weight | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal pain | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal pain | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ||
Line 1,129: | Line 1,226: | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Gaucher's disease|Gaucher disease]]<ref name="pmid23510067">{{cite journal |vauthors=Ayto R, Hughes DA |title=Gaucher disease and myeloma |journal=Crit Rev Oncog |volume=18 |issue=3 |pages=247–68 |date=2013 |pmid=23510067 |doi= |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Gaucher's disease|Gaucher disease]]<ref name="pmid23510067">{{cite journal |vauthors=Ayto R, Hughes DA |title=Gaucher disease and myeloma |journal=Crit Rev Oncog |volume=18 |issue=3 |pages=247–68 |date=2013 |pmid=23510067 |doi= |url=}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | |||
* Accumulatio<nowiki/>n of [[glucocerebroside]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[ | * [[Autosomal recessive]] hereditary deficiency of the enzyme [[glucocerebrosidase]] | ||
* More in Ashkenazi Jews | |||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* | * Positive family history | ||
| align="center" style="background:#F5F5F5;" | - | | align="center" style="background:#F5F5F5;" | - | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 1,143: | Line 1,242: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* Painful [[bone]] lesions | |||
* [[Lymphadenopathy]] | |||
* Yellowish-brown [[Human skin color|skin pigmentation]] | |||
| align="center" style="background:#F5F5F5;" |↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
| align="center" style="background:#F5F5F5;" |↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
Line 1,151: | Line 1,253: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
| align=" | * [[Proteinuria]] | ||
* [[Hematuria]] | |||
| align="left" style="background:#F5F5F5;" | | |||
* Hypocellular [[bone marrow]] | * Hypocellular [[bone marrow]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |NA | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |[[Enzyme]] testing | ||
| align=" | | align="left" style="background:#F5F5F5;" | | ||
* The most common of the [[Lysosomal storage disease|lysosomal storage diseases]] | |||
* Severe neurological complications | |||
* [[Infection|Infections]] | |||
* [[Osteoporosis]] | |||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Niemann-Pick disease]] | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Niemann-Pick disease]]<ref name="pmid23622394">{{cite journal |vauthors=Vanier MT |title=Niemann-Pick diseases |journal=Handb Clin Neurol |volume=113 |issue= |pages=1717–21 |date=2013 |pmid=23622394 |doi=10.1016/B978-0-444-59565-2.00041-1 |url=}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | |||
* Mutations in the ''[[Sphingomyelin phosphodiesterase 1|SMPD1]]'' gene | |||
* Deficiency in the activity of the lysosomal enzyme acid [[sphingomyelinase]] | |||
* Accumulation of [[sphingomyelin]] | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| align=" | |||
| | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Autosomal recessive]] [[lysosomal storage disease]] | |||
* More common in Ashkenazi Jews | |||
| align="left" style="background:#F5F5F5;" | | |||
* Positive family history | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |Nl to ↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Ataxia|Unsteady gait]] | |||
* Slurred [[speech]] | |||
* [[Dysphagia]] | |||
* [[Dystonia]] | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[Proteinuria]] | |||
* [[Hematuria]] | |||
| align="left" style="background:#F5F5F5;" | | |||
* Hypocellular [[bone marrow]] | |||
| align="center" style="background:#F5F5F5;" |NA | |||
| align="center" style="background:#F5F5F5;" |[[Genetic testing]] | |||
| align="left" style="background:#F5F5F5;" | | |||
* [[CNS]] involvement | |||
* [[Supranuclear ocular palsy|Supranuclear gaze palsy]] | |||
* [[Dementia]] | |||
* [[Seizure]] | |||
* Gelastic [[cataplexy]] | |||
* Pulmonary [[Infection|infections]] | |||
* [[Splenic rupture]] | |||
* [[Coronary arteries|Coronary artery]] or [[valvular heart disease]] | |||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Langerhans cell histiocytosis]]<ref name="pmid25281259">{{cite journal |vauthors=DiCaprio MR, Roberts TT |title=Diagnosis and management of langerhans cell histiocytosis |journal=J Am Acad Orthop Surg |volume=22 |issue=10 |pages=643–52 |date=October 2014 |pmid=25281259 |doi=10.5435/JAAOS-22-10-643 |url=}}</ref> | |||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Langerhans cell histiocytosis]] | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Clonal proliferation of Langerhans cells | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Any age | |||
* More common in children between 5-10 years old | |||
* Boys>girls | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | - | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Painful bone swelling | |||
* Scaly erythematous lesions | |||
* [[Lymphadenopathy]] | |||
* [[Cough]] | |||
* [[Dyspnea]] | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Proteinuria]] | |||
* [[Hematuria]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Birbeck [[granules]] on electron microscopy | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Osteolytic lesions on imaging | |||
* Lung nodules on imaging | |||
| align="center" style="background:#F5F5F5;" |Tissue biopsy | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Diabetes insipidus]] | |||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category | |||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ||
Line 1,381: | Line 1,363: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fatigue | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fatigue | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Weight | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Weight | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal pain | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal pain | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ||
Line 1,402: | Line 1,384: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
|} | |} | ||
==Diagnosis== | ==Diagnosis== | ||
==Treatment== | |||
If the splenomegaly underlies hypersplenism, a [[splenectomy]] is indicated and it will correct the problem. After [[splenectomy]], patients have an increased risk for infectious diseases. After [[splenectomy]], patients should be [[vaccine|vaccinated]] against ''[[Haemophilus influenzae]]'' and ''[[Streptococcus pneumoniae]]''. They should receive annual [[influenza vaccination]]. Long-term [[prophylaxis|prophylactic]] [[antibiotic]] should be given. | |||
== Treatment == | |||
[[ | |||
==References== | ==References== |
Latest revision as of 18:38, 3 February 2019
For the patient information page for this topic, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2], Gichoya Judy Wawira [3],
Synonyms and keywords: Spleen enlargement; enlarged spleen; spleen swelling
Overview
Pathophysiology
Causes
The causes of splenomegaly vary widely and range from increased splenic function (such as hemoglobinopathies), splenic congestion due to abnormal blood flow (such as venous obstruction), and splenic infiltration (such as storage disorders and malignancies).
Causes by Pathogenesis
Mechanism | Pathogenesis | Example | |
---|---|---|---|
Increased function | Removal of defective RBCs | ||
Immune hyperplasia | Response to infection (viral, bacterial, fungal, parasitic) | ||
Disordered immunoregulation | |||
Drug reactions | |||
Extramedullary hematopoiesis | |||
Abnormal blood flow | Organ Failure | ||
Vascular |
| ||
Infections |
| ||
Infiltration | Metabolic diseases | ||
Benign and malignant infiltrations |
|
Differentiating Splenomegaly from Other Diseases
Category | Disease | Etiology | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History | Symptoms | Signs | Lab Findings | Imaging | ||||||||||||||||||||||
Fever | Fatigue | Weight | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | CBC | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | |||||||||||
WBC | Hb | Plt | |||||||||||||||||||||||||
Congestive | Cirrhosis[1] | Any age, more common in elderly | – | + | ↑↓ | + | + | ↓ | Nl | + | + | ↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ |
|
|
|
Liver biopsy | |||||
Heart failure[2] | Elderly |
|
– | + | ↑↓ | – | – | ↑ | ↑ | ± | + | ↓ | ↓ | ↑ | Nl | ↑ | ↑ | ↑ | Nl | NA |
|
Echocardiography |
| ||||
Thrombosis of portal, hepatic, or splenic veins[3] | Any age | + | + | ↑ | + | + | ↓ | Nl | ± | + | ↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ |
|
NA |
|
Doppler ultrasonography | ||||||
Malignancy | Lymphoma[4] | Any age, most common malignant splenic tumor |
|
+ | + | ↓ | + | + | Nl | Nl | + | – | ↓ | ↓ | ↓ | High ferritin | ↑ | ↑ | ↑ | Nl |
|
|
Lymph node biopsy | ||||
Leukemia[5] |
|
Elderly, male>female |
|
+ | + | ↓ | + | + | Nl | Nl | ± | + | ↓ | ↓ | ↓ | High ferritin | ↑ | ↑ | ↑ | Nl |
|
NA | Bone marrow examination + clinical manifestation |
| |||
Polycythemia Vera[6] |
|
Mean age >60 years old |
|
– | + | Nl | + | – | Nl | Nl | – | – |
|
Nl to ↑ | ↑ | Nl to ↑ | High ferritin | Nl | Nl | Nl | Nl |
|
NA | WHO criteria for PV | |||
Disease | Etiology | Demography | History | Fever | Fatigue | Weight loss | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | ||
Multiple myeloma[7] | Any age, more common in adults |
|
+ | + | ↓ | + | + | Nl | Nl | + | – | ↓ | ↓ | ↓ | High ferritin | Nl | ↑ | ↑ |
|
Bone marrow examination |
| ||||||
Essential thrombocythemia[8] |
|
Mean age >60 years old, female > male |
|
± | + | Nl | + | + | Nl | Nl | – | – | ↑ | ↑ | ↑↑ | Nl | Nl | Nl | Nl | Nl |
|
|
Bone marrow biopsy | ||||
Primary myelofibrosis[9] |
|
Mean age >60 years old, male> female |
|
– | + | Nl | + | + | Nl | Nl | + | – | ↓ | ↓ | ↑/↓ | Low iron | Nl | ↑ | Nl |
|
Bone marrow biopsy |
| |||||
Primary splenic tumors[10] | Very rare |
|
+ | + | ↓ | + | – | Nl | Nl | – | – |
|
↓ | ↓ | ↓ | Low iron, low ferritin | ↑ | ↑ | ↑ |
|
|
Biopsy |
| ||||
Metastatic solid tumors[11] |
|
Any age, more in adults |
|
+ | + | ↓ | + | + | ↓ | Nl | ± | ± | ↓ | ↓ | ↓ | Low iron, high ferritin | ↑ | ↑ | ↑ |
|
Biopsy |
| |||||
Disease | Etiology | Demography | History | Fever | Fatigue | Weight | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | ||
Infection | Viral | Hepatitis[12] |
|
|
+ | + | ↓ | + | + | Nl | Nl | + | + |
|
↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ | NA | Clinical manifestation + lab tests |
| |||
Infectious mononucleosis[13] |
|
|
+ | + | Nl | + | – | Nl | Nl | + | – |
|
↑ | Nl | ↑ | Nl | ↑ | Nl | Nl | Nl | NA | NA | Clinical manifestation + heterophile antibody test | ||||
Cytomegalovirus[14] |
|
|
+ | + | Nl | + | – | Nl | Nl | + | – |
|
↑ | Nl | ↑ | Nl | ↑ | Nl | Nl | Nl | NA | NA | ELISA | ||||
Bacterial | Salmonella[15] |
|
|
+ | – | Nl | + | – | ↓ | Nl | – | – |
|
↑ | Nl | ↑ | Nl | Nl | Nl | ↑ | NA | NA | Stool test |
| |||
Brucella[16] |
|
|
|
+ | + | Nl | + | – | ↓ | Nl | + | – |
|
↑ | Nl | ↑ | Nl | ↑ | Nl | Nl | NA | NA | Blood culture |
| |||
Tuberculosis[17] |
|
|
|
+ | + | ↓ | + | – | ↓ | Nl | + | – |
|
↑ | Nl | ↑ | Nl | ↑ | ↑ | ↑ |
|
|
Identifying M. tuberculosis in a clinical sample |
| |||
Parasitic | Malaria[18] |
|
|
|
+ | + | Nl | + | + | ↓ | Nl | + | – | ↑ | ↓ | ↑ | Nl | ↑ | Nl | ↑ | NA | ||||||
Kala-azar[19] |
|
|
+ | + | ↓ | + | + | ↓ | Nl | + | + |
|
↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ |
|
NA | Culture |
| ||||
Disease | Etiology | Demography | History | Fever | Fatigue | Weight | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | ||
Inflammation | Sarcoidosis[20] |
|
|
|
+ | + | ↓ | + | + | Nl | Nl | – | – | ↑ | ↓ | ↑ | Nl | Nl | Nl | Nl | Nl | NA |
|
Diagnosis of exclusion |
| ||
Serum sickness[21] |
|
|
|
+ | + | Nl | + | – | ↓ | Nl | – | – | ↓ or ↑
Eosinophilia |
↓ | ↑ | Nl | Nl | Nl | ↑ |
|
NA | Clinical manifestation + recent medication consumption | |||||
Systemic lupus erythematosus[22] |
|
|
|
+ | + | ↓ | + | + | Nl to ↓ | Nl | + | + | ↓ | ↓ | ↓ | ↑ | ↑ | ↑ |
|
Clinical findings + laboratory studies |
| ||||||
Felty syndrome[23] |
|
|
|
+ | + | ↓ | + | + | Nl to ↓ | Nl | + | + |
|
↓ | ↓ | ↓ | Nl | Nl | Nl | Nl | Nl |
|
Clinical findings + laboratory studies | ||||
Infiltrative | Disease | Etiology | Demography | History | Fever | Fatigue | Weight | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | |
Gaucher disease[24] |
|
|
|
- | + | ↓ | + | + | Nl to ↓ | Nl | + | + |
|
↓ | ↓ | ↓ | Nl | Nl | ↑ | ↑ |
|
NA | Enzyme testing |
| |||
Niemann-Pick disease[25] |
|
|
|
- | + | ↑ | + | + | Nl to ↓ | Nl | + | + |
|
↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ |
|
NA | Genetic testing |
| |||
Langerhans cell histiocytosis[26] |
|
|
- | - | + | ↓ | + | - | Nl | Nl | + | - |
|
↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ |
|
|
Tissue biopsy | ||||
Category | Disease | Etiology | Demography | History | Fever | Fatigue | Weight | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings |
Diagnosis
Treatment
If the splenomegaly underlies hypersplenism, a splenectomy is indicated and it will correct the problem. After splenectomy, patients have an increased risk for infectious diseases. After splenectomy, patients should be vaccinated against Haemophilus influenzae and Streptococcus pneumoniae. They should receive annual influenza vaccination. Long-term prophylactic antibiotic should be given.
References
- ↑ Wu Z, Zhou J, Pankaj P, Peng B (December 2012). "Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity". Surg Endosc. 26 (12): 3557–64. doi:10.1007/s00464-012-2366-5. PMID 22710653.
- ↑ Gedela M, Khan M, Jonsson O (September 2015). "Heart Failure". S D Med. 68 (9): 403–5, 407–9. PMID 26489162.
- ↑ Ferri PM, Ferreira AR, Fagundes ED, Liu SM, Roquete ML, Penna FJ (2012). "Portal vein thrombosis in children and adolescents: 20 years experience of a pediatric hepatology reference center". Arq Gastroenterol. 49 (1): 69–76. PMID 22481689.
- ↑ Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Saito T, Tanaka Y (May 2015). "Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma". Hematology. 20 (4): 203–7. doi:10.1179/1607845414Y.0000000192. PMID 25131182.
- ↑ Quest GR, Johnston JB (December 2015). "Clinical features and diagnosis of hairy cell leukemia". Best Pract Res Clin Haematol. 28 (4): 180–92. doi:10.1016/j.beha.2015.10.017. PMID 26614896.
- ↑ Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH (March 2013). "Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage". Eur. J. Haematol. 90 (3): 228–36. doi:10.1111/ejh.12064. PMID 23281576.
- ↑ Grieco A, Manna R, Mancini R, Gambassi G (April 1988). "Massive hepatomegaly following splenectomy for myeloid metaplasia". Am. J. Med. 84 (4): 797. PMID 3400674.
- ↑ Tefferi A, Barbui T (February 2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am. J. Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
- ↑ Cervantes F, Martinez-Trillos A (May 2013). "Myelofibrosis: an update on current pharmacotherapy and future directions". Expert Opin Pharmacother. 14 (7): 873–84. doi:10.1517/14656566.2013.783019. PMID 23514013.
- ↑ Adachi K, Ui M, Nojima H, Takada Y, Enatsu K (August 2011). "Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy". Am. J. Surg. 202 (2): e17–9. doi:10.1016/j.amjsurg.2010.10.002. PMID 21810495.
- ↑ Huprikar NA, Kurtz MT, Mount CA (October 2013). "Massive splenomegaly and lymphopenia: a unique case of obstructive shock". BMJ Case Rep. 2013. doi:10.1136/bcr-2013-201643. PMC 3822246. PMID 24172780.
- ↑ Kumar KJ, Kumar HC, Manjunath VG, Anitha C, Mamatha S (January 2014). "Hepatitis A in children- clinical course, complications and laboratory profile". Indian J Pediatr. 81 (1): 15–9. doi:10.1007/s12098-013-1114-8. PMID 23904062.
- ↑ Gao LW, Xie ZD, Liu YY, Wang Y, Shen KL (February 2011). "Epidemiologic and clinical characteristics of infectious mononucleosis associated with Epstein-Barr virus infection in children in Beijing, China". World J Pediatr. 7 (1): 45–9. doi:10.1007/s12519-011-0244-1. PMID 21191775.
- ↑ Smiechura M, Strużycka M, Konopka W (2014). "Congenital and acquired cytomegalovirus infection and hearing evaluation in children". Otolaryngol Pol. 68 (6): 303–7. doi:10.1016/j.otpol.2014.04.003. PMID 25308607.
- ↑ Rosche KL, Aljasham AT, Kipfer JN, Piatkowski BT, Konjufca V (2015). "Infection with Salmonella enterica Serovar Typhimurium Leads to Increased Proportions of F4/80+ Red Pulp Macrophages and Decreased Proportions of B and T Lymphocytes in the Spleen". PLoS ONE. 10 (6): e0130092. doi:10.1371/journal.pone.0130092. PMC 4466801. PMID 26068006.
- ↑ Roset MS, Ibañez AE, de Souza Filho JA, Spera JM, Minatel L, Oliveira SC, Giambartolomei GH, Cassataro J, Briones G (2014). "Brucella cyclic β-1,2-glucan plays a critical role in the induction of splenomegaly in mice". PLoS ONE. 9 (7): e101279. doi:10.1371/journal.pone.0101279. PMC 4077732. PMID 24983999.
- ↑ Chandni R, Chandni R, Chandni R (2016). "Extra pulmonary tuberculosis presenting as fever with massive splenomegaly and pancytopenia". IDCases. 4: 20–2. doi:10.1016/j.idcr.2016.02.005. PMC 4802818. PMID 27051579.
- ↑ Sumbele IU, Bopda OS, Kimbi HK, Ning TR, Nkuo-Akenji T (November 2015). "Influence of Plasmodium gametocyte carriage on the prevalence of fever, splenomegaly and cardiovascular parameters in children less than 15 years in the Mount Cameroon area: cross sectional study". BMC Infect. Dis. 15: 547. doi:10.1186/s12879-015-1290-4. PMC 4661959. PMID 26612502.
- ↑ Sayyahfar S, Ansari S, Mohebali M, Behnam B (April 2014). "Visceral leishmaniasis without fever in an 11-month-old infant: a rare clinical feature of Kala-azar". Korean J. Parasitol. 52 (2): 189–91. doi:10.3347/kjp.2014.52.2.189. PMC 4028457. PMID 24850963.
- ↑ Modaresi Esfeh J, Culver D, Plesec T, John B (March 2015). "Clinical presentation and protocol for management of hepatic sarcoidosis". Expert Rev Gastroenterol Hepatol. 9 (3): 349–58. doi:10.1586/17474124.2015.958468. PMID 25473783.
- ↑ Chiong FJ, Loewenthal M, Boyle M, Attia J (December 2015). "Serum sickness-like reaction after influenza vaccination". BMJ Case Rep. 2015. doi:10.1136/bcr-2015-211917. PMC 4691861. PMID 26677148.
- ↑ Yu C, Gershwin ME, Chang C (2014). "Diagnostic criteria for systemic lupus erythematosus: a critical review". J. Autoimmun. 48-49: 10–3. doi:10.1016/j.jaut.2014.01.004. PMID 24461385.
- ↑ Huang T, Liu M, Xu G (January 2014). "Felty's syndrome with hyperthyroidism: a case report and literature review". Int J Rheum Dis. 17 (1): 122–4. doi:10.1111/1756-185X.12117. PMID 24472276.
- ↑ Ayto R, Hughes DA (2013). "Gaucher disease and myeloma". Crit Rev Oncog. 18 (3): 247–68. PMID 23510067.
- ↑ Vanier MT (2013). "Niemann-Pick diseases". Handb Clin Neurol. 113: 1717–21. doi:10.1016/B978-0-444-59565-2.00041-1. PMID 23622394.
- ↑ DiCaprio MR, Roberts TT (October 2014). "Diagnosis and management of langerhans cell histiocytosis". J Am Acad Orthop Surg. 22 (10): 643–52. doi:10.5435/JAAOS-22-10-643. PMID 25281259.